Literature DB >> 16612216

Depression in neurological disorders: an update.

Hugh Rickards1.   

Abstract

PURPOSE OF REVIEW: Depressions are a heterogeneous group of conditions that contribute significantly to impairments in quality of life, independent of the severity of neurological illness. Depression may predate neurological signs and symptoms in the evolution of neurodegenerative disorders, and there is some evidence that depressive illness itself may be a risk factor in the aetiology of some dementias. This review aims to summarize the relevant current literature on diagnosis, aetiology and treatment of depression in neurology. RECENT
FINDINGS: Diagnosing depression in neurological conditions can be particularly difficult because of communication difficulties and changes in emotional expression as a result of the underlying neurological disease. Rating scales loaded towards somatic symptoms can show poor validity for screening or rating of severity in this setting. The evidence for the treatment of depression in neurological disease is scant, and often the treatment advice is based on consensus views of clinicians. Nevertheless, there have been some clinical trials, which are reported.
SUMMARY: Depression is common in neurology. It is underrecognized and undertreated. Recent research has allowed us to define depression more clearly in this setting. Trials of treatment are urgently needed, especially as depression is a significant factor in quality of life and may affect prognosis.

Entities:  

Mesh:

Year:  2006        PMID: 16612216     DOI: 10.1097/01.yco.0000218601.17722.5b

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  11 in total

1.  Psychometric properties of the Hamilton Depression Rating Scale in multiple sclerosis.

Authors:  Simona Raimo; Luigi Trojano; Daniele Spitaleri; Vittorio Petretta; Dario Grossi; Gabriella Santangelo
Journal:  Qual Life Res       Date:  2015-02-11       Impact factor: 4.147

2.  Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study.

Authors:  Daniela Di Giuda; Giovanni Camardese; Anna Rita Bentivoglio; Fabrizio Cocciolillo; Arianna Guidubaldi; Lorella Pucci; Isabella Bruno; Luigi Janiri; Alessandro Giordano; Alfonso Fasano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-14       Impact factor: 9.236

3.  Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study.

Authors:  Eric A Epping; James A Mills; Leigh J Beglinger; Jess G Fiedorowicz; David Craufurd; Megan M Smith; Mark Groves; Kelly R Bijanki; Nancy Downing; Janet K Williams; Jeffrey D Long; Jane S Paulsen
Journal:  J Psychiatr Res       Date:  2013-06-19       Impact factor: 4.791

4.  Neurological diseases and risk of suicide attempt: a case-control study.

Authors:  Astrid Eliasen; Kim Peder Dalhoff; Henrik Horwitz
Journal:  J Neurol       Date:  2018-03-21       Impact factor: 4.849

Review 5.  Glutamate Efflux across the Blood-Brain Barrier: New Perspectives on the Relationship between Depression and the Glutamatergic System.

Authors:  Benjamin Fredrick Gruenbaum; Alexander Zlotnik; Amit Frenkel; Ilya Fleidervish; Matthew Boyko
Journal:  Metabolites       Date:  2022-05-20

Review 6.  Depressive symptoms in neurodegenerative diseases.

Authors:  Miquel Baquero; Nuria Martín
Journal:  World J Clin Cases       Date:  2015-08-16       Impact factor: 1.337

Review 7.  Natural Compounds as Medical Strategies in the Prevention and Treatment of Psychiatric Disorders Seen in Neurological Diseases.

Authors:  Esra Küpeli Akkol; Irem Tatlı Çankaya; Gökçe Şeker Karatoprak; Elif Carpar; Eduardo Sobarzo-Sánchez; Raffaele Capasso
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

8.  Longitudinal Relationships Between Subjective Cognitive Decline and Objective Memory: Depressive Symptoms Mediate Between-Person Associations.

Authors:  Nikki L Hill; Sakshi Bhargava; Emily Bratlee-Whitaker; Jennifer R Turner; Monique J Brown; Jacqueline Mogle
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

9.  Post-marketing observational program of the effectiveness of fluvoxamine for the treatment of depression in patients with neurological disorders: the FRIENDS study.

Authors:  Nikolay N Yahno; Anastasia V Fedotova
Journal:  Neuropsychiatr Dis Treat       Date:  2017-11-02       Impact factor: 2.570

10.  Prevalence of depression and associated factors among epileptic patients at Ilu Ababore zone hospitals, South West Ethiopia, 2017: a cross‑sectional study.

Authors:  Nigus Alemnew Engidaw; Lemi Bacha; Adamu Kenea
Journal:  Ann Gen Psychiatry       Date:  2020-03-11       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.